What is Respiratory Technology?
Respiratory Technology operates at the intersection of medical device innovation and gastroenterology, specializing in the development of advanced pH sensing technology. The company distinguishes itself by providing the first real-time sensors capable of functioning accurately in non-liquid environments, a breakthrough that addresses long-standing limitations in traditional esophageal monitoring. By focusing on the diagnostic and therapeutic continuum, the firm provides clinicians with actionable data to improve patient outcomes in complex disease states. Their market position is defined by a rigorous adherence to engineering precision and a deep understanding of the reflux disease landscape, allowing them to bridge the gap between complex physiological monitoring and accessible clinical solutions.
How much funding has Respiratory Technology raised?
Respiratory Technology has raised a total of $813K across 2 funding rounds:
Debt
$350K
Debt
$463K
Debt (2020): $350K with participation from PPP
Debt (2021): $463K led by PPP
Key Investors in Respiratory Technology
PPP
Public-Private Partnership
What's next for Respiratory Technology?
With the recent capital deployment, Respiratory Technology is positioned to accelerate its expansion across the global diagnostic market. The strategic focus will likely shift toward scaling manufacturing capabilities and broadening the clinical application of its sensor technology. As the company matures, the integration of these diagnostic tools into standard clinical workflows will be critical for maintaining its competitive edge. Future growth trajectories suggest a continued emphasis on research and development, ensuring that the firm remains at the forefront of non-invasive reflux diagnostics while exploring new therapeutic avenues to address the broader needs of the gastroenterology sector.
See full Respiratory Technology company page
